Nifty
Sensex
:
:
11886.35
40322.58
-51.15 (-0.43%)
-164.85 (-0.41%)

Pharmaceuticals & Drugs

Rating :
51/99  (View)

BSE: 532531 | NSE: STAR

371.90
-1.20 (-0.32%)
10-Dec-2019 | 12:29PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  373.70
  •  377.50
  •  371.05
  •  373.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  89420
  •  332.55
  •  551.40
  •  288.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,340.32
  • 6.85
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,045.14
  • 0.80%
  • 1.29

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 31.28%
  • 0.00%
  • 13.74%
  • FII
  • DII
  • Others
  • 3.79%
  • 17.26%
  • 33.93%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 20.29
  • -7.67

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 14.48
  • -2.73

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 198.64
  • -2.26

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.77
  • 22.43
  • 11.48

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.06
  • 3.34
  • 2.21

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.61
  • 18.07
  • 14.04

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Net Sales
715.09
732.63
-2.39%
685.80
472.69
45.08%
839.70
669.89
25.35%
794.50
748.79
6.10%
Expenses
568.50
633.03
-10.19%
564.88
429.89
31.40%
680.97
577.63
17.89%
667.41
617.83
8.02%
EBITDA
146.59
99.60
47.18%
120.92
42.80
182.52%
158.73
92.26
72.05%
127.09
130.96
-2.96%
EBIDTM
20.50%
13.59%
17.63%
9.05%
18.90%
13.77%
16.00%
17.49%
Other Income
14.07
7.73
82.02%
10.25
6.47
58.42%
14.78
16.06
-7.97%
0.83
15.66
-94.70%
Interest
40.42
48.48
-16.63%
35.34
16.75
110.99%
62.65
45.47
37.78%
50.09
49.77
0.64%
Depreciation
42.00
44.49
-5.60%
42.89
29.01
47.85%
43.82
44.34
-1.17%
40.67
37.95
7.17%
PBT
161.68
6.97
2,219.66%
46.29
0.56
8,166.07%
76.01
-3.14
-
37.90
52.58
-27.92%
Tax
7.38
1.61
358.39%
3.12
-13.53
-
11.05
-4.96
-
6.33
2.01
214.93%
PAT
154.30
5.36
2,778.73%
43.17
14.09
206.39%
64.96
1.82
3,469.23%
31.57
50.57
-37.57%
PATM
21.58%
0.73%
6.29%
2.98%
7.74%
0.27%
3.97%
6.75%
EPS
15.97
-1.34
-
0.41
-0.48
-
5.31
63.65
-91.66%
32.77
9.56
242.78%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Net Sales
3,035.09
3,011.68
3,344.37
3,826.22
2,862.19
1,195.85
1,340.96
961.76
2,550.04
1,695.84
1,304.77
Net Sales Growth
15.67%
-9.95%
-12.59%
33.68%
139.34%
-10.82%
39.43%
-62.28%
50.37%
29.97%
 
Cost Of Goods Sold
1,388.07
1,466.00
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
1,264.39
805.65
700.90
Gross Profit
1,647.02
1,545.67
1,965.53
2,545.05
1,359.90
635.37
626.30
469.94
1,285.66
890.19
603.86
GP Margin
54.27%
51.32%
58.77%
66.52%
47.51%
53.13%
46.71%
48.86%
50.42%
52.49%
46.28%
Total Expenditure
2,481.76
2,561.63
3,108.66
3,309.30
2,481.62
967.00
1,117.54
861.18
2,059.36
1,369.22
1,117.84
Power & Fuel Cost
-
54.67
51.33
33.87
77.18
16.02
18.56
12.84
54.24
30.23
24.58
% Of Sales
-
1.82%
1.53%
0.89%
2.70%
1.34%
1.38%
1.34%
2.13%
1.78%
1.88%
Employee Cost
-
442.58
434.05
419.16
357.69
172.06
157.18
120.30
302.74
219.57
177.01
% Of Sales
-
14.70%
12.98%
10.95%
12.50%
14.39%
11.72%
12.51%
11.87%
12.95%
13.57%
Manufacturing Exp.
-
119.16
115.97
137.47
119.23
41.37
35.76
44.43
89.60
63.83
45.15
% Of Sales
-
3.96%
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
3.51%
3.76%
3.46%
General & Admin Exp.
-
206.67
194.38
172.63
198.71
86.25
66.37
58.16
182.12
159.16
86.87
% Of Sales
-
6.86%
5.81%
4.51%
6.94%
7.21%
4.95%
6.05%
7.14%
9.39%
6.66%
Selling & Distn. Exp.
-
173.21
208.85
161.12
129.57
61.37
66.67
39.94
116.07
88.02
73.40
% Of Sales
-
5.75%
6.24%
4.21%
4.53%
5.13%
4.97%
4.15%
4.55%
5.19%
5.63%
Miscellaneous Exp.
-
99.34
725.25
1,103.88
96.95
29.44
58.33
93.69
50.21
2.76
73.40
% Of Sales
-
3.30%
21.69%
28.85%
3.39%
2.46%
4.35%
9.74%
1.97%
0.16%
0.76%
EBITDA
553.33
450.05
235.71
516.92
380.57
228.85
223.42
100.58
490.68
326.62
186.93
EBITDA Margin
18.23%
14.94%
7.05%
13.51%
13.30%
19.14%
16.66%
10.46%
19.24%
19.26%
14.33%
Other Income
39.93
322.44
920.64
398.08
102.37
38.57
60.23
34.20
31.67
69.70
23.57
Interest
188.50
205.34
196.24
183.10
168.17
47.44
108.88
79.45
194.83
146.65
75.91
Depreciation
169.38
171.85
193.93
198.69
131.25
64.03
56.48
30.86
104.30
63.90
49.19
PBT
321.88
395.30
766.17
533.20
183.50
155.95
118.30
24.48
223.22
185.77
85.41
Tax
27.88
14.49
21.41
51.19
42.45
147.60
40.86
11.15
38.68
45.19
21.90
Tax Rate
8.66%
3.69%
2.96%
10.30%
29.87%
99.35%
44.53%
1.54%
14.18%
24.25%
15.32%
PAT
294.00
372.93
681.31
399.38
113.21
1.57
50.89
712.39
224.48
122.45
109.68
PAT before Minority Interest
295.40
378.19
701.18
445.58
99.68
0.98
50.89
713.44
234.01
141.18
121.04
Minority Interest
1.40
-5.26
-19.87
-46.20
13.53
0.59
0.00
-1.05
-9.53
-18.73
-11.36
PAT Margin
9.69%
12.38%
20.37%
10.44%
3.96%
0.13%
3.80%
74.07%
8.80%
7.22%
8.41%
PAT Growth
309.24%
-45.26%
70.59%
252.78%
7110.83%
-96.91%
-92.86%
217.35%
83.32%
11.64%
 
Unadjusted EPS
54.46
36.25
74.25
44.73
13.14
141.85
298.56
121.47
38.65
26.11
26.49

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Shareholder's Funds
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
1,371.48
1,282.78
831.07
Share Capital
89.55
89.50
89.42
89.35
59.62
59.57
58.80
58.38
57.74
89.38
Total Reserves
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
947.06
1,963.94
1,310.34
1,222.95
724.09
Non-Current Liabilities
2,348.41
2,067.29
2,048.67
2,760.03
285.79
306.42
900.59
1,132.57
2,012.89
1,459.17
Secured Loans
1,806.50
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
1,054.31
1,387.39
778.70
Unsecured Loans
0.06
0.23
14.84
12.13
17.16
1.24
0.00
0.00
622.45
678.17
Long Term Provisions
21.52
16.55
25.19
14.45
6.02
16.56
57.25
66.19
0.00
0.00
Current Liabilities
2,703.27
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
2,791.73
923.65
684.15
Trade Payables
894.19
712.07
774.09
775.40
234.41
262.31
463.08
585.04
419.85
445.23
Other Current Liabilities
249.77
129.98
819.08
347.93
502.47
127.27
651.65
1,369.80
305.00
64.64
Short Term Borrowings
1,339.02
944.39
1,393.96
700.48
203.03
224.56
599.89
684.65
0.00
0.00
Short Term Provisions
220.29
112.86
116.73
68.19
80.03
93.23
82.66
152.24
198.80
174.28
Total Liabilities
7,853.33
6,584.90
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
5,342.24
4,491.79
3,232.89
Net Block
3,567.19
2,903.00
2,909.03
2,678.68
701.36
554.53
3,016.72
3,187.64
2,328.27
1,856.59
Gross Block
4,046.10
3,229.03
3,186.12
2,825.43
1,080.55
907.33
3,514.29
3,644.82
2,626.71
2,080.70
Accumulated Depreciation
478.92
326.03
277.09
146.75
379.19
352.80
497.57
457.19
298.44
224.11
Non Current Assets
4,808.08
4,101.31
4,243.05
3,845.20
1,039.91
787.65
3,383.87
3,711.33
2,521.48
2,282.61
Capital Work in Progress
506.00
620.29
780.18
814.88
171.17
99.47
241.44
285.03
191.46
84.66
Non Current Investment
494.34
350.08
315.66
127.19
68.76
41.80
0.00
0.00
1.76
341.36
Long Term Loans & Adv.
223.69
197.22
222.56
201.83
96.72
90.40
118.75
229.99
0.00
0.00
Other Non Current Assets
16.86
30.72
15.62
22.62
1.91
1.45
6.96
8.67
0.00
0.00
Current Assets
3,045.26
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
1,625.27
1,960.40
950.29
Current Investments
284.75
311.48
1,279.54
1,213.76
561.29
401.24
0.06
0.00
0.00
0.00
Inventories
870.70
552.02
732.80
613.14
207.68
175.99
442.33
479.93
312.00
233.42
Sundry Debtors
987.18
882.18
995.91
1,032.97
389.96
364.00
483.23
538.44
383.78
420.27
Cash & Bank
516.65
303.33
329.48
311.59
146.88
231.15
165.74
259.73
339.45
91.20
Other Current Assets
385.98
138.84
209.70
245.90
123.64
136.26
319.58
347.17
925.17
205.40
Short Term Loans & Adv.
249.11
295.75
244.39
97.54
54.46
79.06
44.38
91.79
850.18
150.94
Net Current Assets
341.99
584.29
687.95
1,622.91
409.50
601.26
-386.35
-1,166.46
1,036.75
266.14
Total Assets
7,853.34
6,584.90
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98
5,342.23
4,491.80
3,232.90

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Cash From Operating Activity
60.05
187.07
288.14
73.25
83.40
-271.68
134.26
457.10
323.93
89.61
PBT
344.37
705.80
497.14
146.44
992.01
2,889.87
949.49
272.69
186.37
142.94
Adjustment
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
113.84
178.94
42.76
Changes in Working Capital
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
128.87
-2.09
-82.37
Cash after chg. in Working capital
115.82
240.63
346.76
150.29
139.37
-145.81
223.00
515.40
363.23
103.33
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
-58.30
-39.29
-13.72
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
-656.47
-941.00
-147.64
Net Fixed Assets
-48.49
677.20
-236.66
-535.93
-66.57
-119.10
-38.27
-18.46
-42.91
-26.86
Net Investments
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
77.70
653.52
-578.46
Others
283.09
-842.25
-306.76
-210.32
40.35
3,947.38
1,353.35
-715.71
-1,551.61
457.68
Cash from Financing Activity
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
89.36
850.09
91.64
Net Cash Inflow / Outflow
105.83
-246.03
-60.33
792.35
-285.98
486.88
-49.23
-110.01
233.03
33.60
Opening Cash & Equivalents
256.16
515.08
1,110.74
298.91
586.00
132.02
211.93
325.17
79.00
45.88
Closing Cash & Equivalent
365.89
256.16
515.08
1,110.74
298.42
586.00
132.02
212.27
325.17
78.78

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Book Value (Rs.)
294.94
274.26
306.41
296.83
191.91
168.99
343.78
233.49
220.07
190.06
ROA
5.24%
9.59%
5.79%
2.03%
0.04%
1.48%
14.07%
4.76%
3.66%
4.36%
ROE
14.84%
27.00%
16.53%
5.25%
0.09%
3.36%
42.16%
17.77%
13.87%
21.45%
ROCE
11.02%
16.07%
10.75%
7.54%
10.92%
7.76%
21.08%
12.82%
11.96%
10.93%
Fixed Asset Turnover
0.83
1.04
1.27
1.47
1.21
0.61
0.27
0.82
0.72
0.80
Receivable days
113.28
102.49
96.77
90.73
114.71
114.80
193.43
65.68
86.42
105.79
Inventory Days
86.21
70.11
64.20
52.34
58.37
83.78
174.61
56.40
58.62
56.75
Payable days
114.64
116.23
117.33
75.51
76.81
112.69
253.28
92.58
119.83
129.46
Cash Conversion Cycle
84.85
56.37
43.64
67.55
96.27
85.89
114.76
29.50
25.22
33.08
Total Debt/Equity
1.22
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
1.79
Interest Cover
2.91
4.68
3.71
1.85
4.13
1.84
10.12
2.40
2.27
2.88

News Update


  • Strides Pharma’s arm gets USFDA’s tentative nod for Diclofenac Potassium Softgel Capsules
    4th Dec 2019, 11:08 AM

    The US market for Diclofenac Potassium Softgel Capsules, 25 mg is approximately $30 million

    Read More
  • Strides Pharma re-launches Ranitidine tablets (Rx) for US market
    8th Nov 2019, 12:31 PM

    The company has now completed comprehensive testing of several of its batches available in market and in stock meeting the limits prescribed by the USFDA

    Read More
  • Strides Pharma Science reports consolidated net profit of Rs 142 crore in Q2FY20
    25th Oct 2019, 12:08 PM

    Total consolidated income of the company increased by 37.51% at Rs 728.08 crore for Q2FY20

    Read More
  • Strides Pharma Scien - Quarterly Results
    25th Oct 2019, 11:52 AM

    Read More
  • Strides Pharma Science gets EIR from USFDA for Alathur facility
    23rd Oct 2019, 09:12 AM

    The inspection conducted in August 2019 had concluded with Zero 483 observations

    Read More
  • Strides Pharma Science’s arm gets USFDA’s nod for Solifenacin Succinate Tablets
    27th Sep 2019, 10:31 AM

    The US market for Solifenacin Succinate Tablets, 5 mg and 10 mg is approximately $820 million

    Read More
  • Strides Pharma Science receives IR from USFDA for Ranitidine tablets
    27th Sep 2019, 09:26 AM

    The Company has suspended sales of ranitidine tablets in the US market until such time it has clarity of next steps

    Read More
  • Strides Pharma Science receives approval for Rx, OTC Ranitidine tablets
    25th Sep 2019, 14:06 PM

    Ranitidine tablets is amongst the top 5 products sold by the company in the USA

    Read More
  • Strides Pharma Science’s board approves incremental investments in Stelis
    20th Sep 2019, 14:08 PM

    The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space

    Read More
  • Strides Pharma Science’s arm acquires strategic stake in Fairmed
    11th Sep 2019, 09:39 AM

    Under the terms of the agreement, SPG will hold 70% of the issued capital of Fairmed

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.